# US 2021/0275696 A1 · Novel compound binding to designer receptor, imaging method for designer receptor, agonist or antagonist, therapeutic agent, companion diagnostic agent, and imaging method for nerve cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275696 A1
- Document ID: US20210275696A1
- Status: Published application
- Kind: A1
- Application number: 17/253,913
- Filed: 2019-06-21
- Published: 2021-09-09
- Earliest claimed: 2018-06-21
- Assignees: National Institutes for Quantum and Radiological Science and Technology
- Applicants: National Institutes for Quantum and Radiological Science and Technology
- Inventors: Takafumi MINAMIMOTO; Yuji NAGAI; Bin JI; Naohisa MIYAKAWA; Makoto HIGUCHI; Tetsuya SUHARA
- Web page: https://patentgrep.com/patent/US20210275696A1

## CPC

- A61K 51/047: {Benzodiazepines}
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 59/002: {Heterocyclic compounds}
- C07D 243/38: [b, e]- or [b, f]-condensed with six-membered rings
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The purpose of the present invention is to provide a technique for imaging the brain of a live animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain parmeability, high receptor selectivity and high quantitativity, is used for imaging a live animal body. A dibenzoazepine derivative is used for treating a disease in which hM4D receptor or hM3D receptor participates. Further, a radiolabeled dibenzoazepine derivative is used for imaging an axonal end which is innervated by a nerve cell.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A compound represented by Formula (II) or a pharmaceutically acceptable salt or solvate thereof:

### Claim 18 (depends on 17)

A composition comprising
the compound or a pharmaceutically acceptable salt or solvate thereof according to claim 17.

### Claim 19 (depends on 17)

A method for imaging an hM4D or an hM3D in a brain of a live animal subject, the method comprising:
acquiring data on a distribution and/or an amount of expression of the hM4D or the hM3D in the brain containing a cell having an introduced gene encoding a mutated human M4 muscarinic acetylcholine receptor (hM4D) or a mutated human M3 muscarinic acetylcholine receptor (hM3D)
in the live animal subject administered with the compound or a pharmaceutically acceptable salt or solvate thereof according to claim 17,
the compound or a pharmaceutically acceptable salt or solvate thereof being allowed to migrate into the brain to selectively bind to the hM4D or the hM3D expressed by the gene, wherein
the data is acquired by detecting radiation emitted from the compound or a pharmaceutically acceptable salt or solvate thereof selectively binding to the hM4D or the hM3D in the brain.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the compound or a pharmaceutically acceptable salt or solvate thereof emitting radiation in a dose of 2 times or more for an hM4D-expressed site or 1.4 times or more for an hM3D-expressed site that of an unexpressed site as detected by imaging over a predetermined period from peripheral administration.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the live animal subject is a live primate subject,
the predetermined period is 30 to 90 minutes, and
the dose to be detected is 6.3 g/cc or more for the hM4D-expressed site or 3.7 g/cc or more for the hM3D-expressed site when the dose is 2.5 g/cc or less for a whole brain comprising the unexpressed site as expressed as an index normalized to an amount of administration and a body weight.

### Claim 22

A method for imaging a brain activity of a live animal subject, the method comprising:
acquiring data on modulation of an activity of an hM4D- or hM3D-expressing cell in the brain containing a cell having an introduced gene encoding a mutated human M4 muscarinic acetylcholine receptor (hM4D) or a mutated human M3 muscarinic acetylcholine receptor (hM3D)
in the live animal subject administered with a compound or a pharmaceutically acceptable salt or solvate thereof that selectively binds to the hM4D or the hM3D, the compound being represented by Formula (I):
wherein one or more atoms are or are not radioisotopes of the atom or atoms,
the compound or a pharmaceutically acceptable salt or solvate thereof being allowed to migrate into the brain to selectively bind to the hM4D or the hM3D expressed by the gene.

### Claim 23

An antagonist or an agonist comprising: a substance that selectively binds to a mutated human M4 muscarinic acetylcholine receptor (hM4D) or a mutated human M3 muscarinic acetylcholine receptor (hM3D) introduced into a cell in a brain of a live animal subject,
the substance being a compound represented by Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein one or more atoms are or are not radioisotopes of the atom or atoms.

### Claim 24 (depends on 23)

The agonist according to claim 23, wherein the mutated receptor is the mutated human M3 muscarinic acetylcholine receptor (hM3D).

### Claim 25

A pharmaceutical comprising:
a substance that selectively binds to a mutated human M4 muscarinic acetylcholine receptor (hM4D) or a mutated human M3 muscarinic acetylcholine receptor (hM3D) introduced into a cell in a brain of a live primate subject,
the substance being a compound represented by Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein one or more atoms are or are not radioisotopes of the atom or atoms.

### Claim 26

A companion diagnostic agent comprising:
a substance that selectively binds to a mutated human M4 muscarinic acetylcholine receptor (hM4D) or a mutated human M3 muscarinic acetylcholine receptor (hM3D) introduced into a cell in a brain of a live primate subject,
the substance being a compound represented by Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein one or more atoms are or are not radioisotopes of the atom or atoms.

### Claim 27 (depends on 17)

A method for imaging axon terminals of a nerve cell having an introduced gene encoding a mutated human M4 muscarinic acetylcholine receptor (hM4D) or a mutated human M3 muscarinic acetylcholine receptor (hM3D) in a brain of a live animal subject, the method comprising:
allowing the compound or a pharmaceutically acceptable salt or solvate thereof according to claim 17 to migrate into the brain to selectively bind to the hM4D or the hM3D.

### Claim 28 (depends on 27)

The method according to claim 27, the method being a method for imaging a nerve cell across a plurality of regions in a brain of a live animal subject,
the nerve cell including a dendrite-containing body belonging to a first region and having axon terminals belonging to a region different from the first region,
the first region having an introduced gene encoding a mutated human M4 muscarinic acetylcholine receptor (hM4D) or a mutated human M3 muscarinic acetylcholine receptor (hM3D), the method comprising:
acquiring data on a distribution and/or an amount of expression of the hM4D or the hM3D in the axon terminal in the live animal subject administered with the radiolabeled compound or a pharmaceutically acceptable salt or solvate thereof that is allowed to migrate into the brain to selectively bind to the hM4D or the hM3D, wherein
the data is acquired by detecting radiation emitted from the radiolabeled compound or a pharmaceutically acceptable salt or solvate thereof selectively binding to the hM4D or the hM3D.
